Aptamers

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on […]

Biopharmaceutical company Basking Biosciences has revealed positive Phase I study results for its reversible thrombolytic therapeutic for ischaemic stroke.  The company’s novel von Willebrand Factor (vWF)-targeting thrombolytic agent, BB-031 demonstrated safety and tolerability following a single intravenous dose.   The study results were presented at the American Heart Association International Stroke Conference (ISC) 2023 in Dallas, […]

Ixaka and SomaLogic have created a research collaboration to support the development of aptamer-based bispecific therapeutics. The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer reagents (modified aptamers that bind tightly and specifically to protein targets) previously identified and screened by SomaLogic as potential candidates for combination with Ixaka’s anti-CD3 aptamers. Ixaka is […]